Journal of Pediatric Epilepsy 2023; 12(03): 091-097
DOI: 10.1055/s-0042-1758660
Original Article

A Retrospective Study of the Profile and Outcome of Children with Dravet Syndrome in a Tertiary Care Hospital of Southern India

1   Department of Paediatric Neurology, Manipal Hospital, Bangalore, Karnataka, India
1   Department of Paediatric Neurology, Manipal Hospital, Bangalore, Karnataka, India
Gowthami Lagudu
2   Department of Paediatrics, Manipal Hospital, Bangalore, Karnataka, India
Mitesh Shetty
3   Department of Genetics, Manipal Hospital, Bangalore, Karnataka, India
Sridevi Hegde
3   Department of Genetics, Manipal Hospital, Bangalore, Karnataka, India
› Author Affiliations


Objective Dravet syndrome (DS) is an epileptic syndrome that shares similarities with febrile seizures (FS), especially before 1 year of age, making it challenging to differentiate the two. We describe the profile of DS, with emphasis on the first year of life that can aid in early diagnosis.

Methods The clinical, investigative, treatment, and outcome profiles of DS patients presenting to the outpatient department (OPD) between October 2016 and December 2021 in a single tertiary care center in South India were analyzed.

Results Seventeen children were studied, with median age at presentation of 30 (interquartile range [IQR] 10, 47) months. The median age at seizure onset was 5 (IQR 3, 6) months. First seizure semiology were generalized tonic-clonic (GTCS) (35.3%), focal (52.9%), and myoclonic (11.8%). Fever preceding first seizure was seen in 76.5%. Status epilepticus (SE; ≥30 minutes) and prolonged seizures (>10 minutes) were seen in 41.2% each, and >5 seizures were seen in 82.4% in the first year of life. The most frequent subsequent seizure types were focal seizures (76.5%) and GTCS (76.5%). Other seizure triggers included vaccination (52.9%), light (17.6%), and Hot-bath (5.8%). Delayed developmental milestones for age were found in 52.9% at diagnosis. Magnetic resonance imaging (MRI) brain and electroencephalogram were normal in 76.4% each. Pathogenic/likely pathogenic variants in SCN1A gene were seen in 64.7%. Average of 3.9 anti-seizure medications were used. After optimization of treatment seizure frequency reduced in 40% and 4/15 (26.6%) had SE.

Conclusion In addition to characteristic clinical profile of DS we observed atypical presentations: an earlier age of seizure onset and afebrile seizure at onset. Delayed diagnosis was noted. Seizure control improved and SE reduced on optimal treatment.

Publication History

Received: 13 June 2022

Accepted: 25 September 2022

Article published online:
21 November 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Rosander C, Hallböök T. Dravet syndrome in Sweden: a population-based study. Dev Med Child Neurol 2015; 57 (07) 628-633
  • 2 Hattori J, Ouchida M, Ono J. et al. A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia 2008; 49 (04) 626-633
  • 3 Dravet Syndrome - NORD (National Organization for Rare Disorders). NORD (National Organization for Rare Disorders). 2022 . Accessed May 05, 2022, at:
  • 4 Li W, Schneider AL, Scheffer IE. Defining Dravet syndrome: an essential pre-requisite for precision medicine trials. Epilepsia 2021; 62 (09) 2205-2217
  • 5 Ragona F, Brazzo D, De Giorgi I. et al. Dravet syndrome: early clinical manifestations and cognitive outcome in 37 Italian patients. Brain Dev 2010; 32 (01) 71-77
  • 6 Petrelli C, Passamonti C, Cesaroni E. et al. Early clinical features in Dravet syndrome patients with and without SCN1A mutations. Epilepsy Res 2012; 99 (1-2): 21-27
  • 7 Cetica V, Chiari S, Mei D. et al. Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations. Neurology 2017; 88 (11) 1037-1044
  • 8 Zuberi SM, Wirrell E, Yozawitz E. et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022; 63 (06) 1349-1397
  • 9 Fisher RS, Cross JH, French JA. et al. Operational classification of seizure types by the International League against epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58 (04) 522-530
  • 10 Miller DT, Lee K, Chung WK. et al; ACMG Secondary Findings Working Group. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021; 23 (08) 1381-1390
  • 11 Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011; 52 (Suppl. 02) 3-9
  • 12 Harkin LA, McMahon JM, Iona X. et al; Infantile Epileptic Encephalopathy Referral Consortium. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 2007; 130 (Pt 3): 843-852
  • 13 Bremer A, Lossius MI, Nakken KO. Dravet syndrome—considerable delay in making the diagnosis. Acta Neurol Scand 2012; 125 (05) 359-362
  • 14 McIntosh AM, McMahon J, Dibbens LM. et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. Lancet Neurol 2010; 9 (06) 592-598
  • 15 Catterall WA. Dravet syndrome: a sodium channel interneuronopathy. Curr Opin Physiol 2018; 2: 42-50
  • 16 Striano P, Mancardi MM, Biancheri R. et al. Brain MRI findings in severe myoclonic epilepsy in infancy and genotype-phenotype correlations. Epilepsia 2007; 48 (06) 1092-1096
  • 17 Scheffer IE, Zhang YH, Jansen FE, Dibbens L. Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?. Brain Dev 2009; 31 (05) 394-400
  • 18 Steel D, Symonds JD, Zuberi SM, Brunklaus A. Dravet syndrome and its mimics: Beyond SCN1A. Epilepsia 2017; 58 (11) 1807-1816
  • 19 Marini C, Scheffer IE, Nabbout R. et al. SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis. Epilepsia 2009; 50 (07) 1670-1678
  • 20 Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA. SCN1A mutations and epilepsy. Hum Mutat 2005; 25 (06) 535-542
  • 21 Sun H, Zhang Y, Liu X. et al. Analysis of SCN1A mutation and parental origin in patients with Dravet syndrome. J Hum Genet 2010; 55 (07) 421-427
  • 22 Depienne C, Trouillard O, Saint-Martin C. et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet 2009; 46 (03) 183-191
  • 23 Cross JH, Caraballo RH, Nabbout R, Vigevano F, Guerrini R, Lagae L. Dravet syndrome: treatment options and management of prolonged seizures. Epilepsia 2019; 60 (Suppl. 03) S39-S48
  • 24 Takayama R, Fujiwara T, Shigematsu H. et al. Long-term course of Dravet syndrome: a study from an epilepsy center in Japan. Epilepsia 2014; 55 (04) 528-538
  • 25 Fujiwara T, Watanabe M, Takahashi Y, Higashi T, Yagi K, Seino M. Long-term course of childhood epilepsy with intractable grand mal seizures. Jpn J Psychiatry Neurol 1992; 46 (02) 297-302
  • 26 Kapoor D, Anand A, Sharma S. et al. Dravet syndrome: a case series. Indian J Pediatr 2021; 88 (01) 82-82
  • 27 Wirrell EC, Laux L, Franz DN. et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia 2013; 54 (09) 1595-1604
  • 28 Gulati S, Sinha R, Madaan P. Ethical, social, and economic challenges in managing a child with Dravet syndrome in a developing country. J Pediatr Epilepsy 2020; 9 (03) 94-96
  • 29 Lattanzi S, Brigo F, Trinka E. et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs 2018; 78 (17) 1791-1804
  • 30 Lattanzi S, Trinka E, Striano P. et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia 2020; 61 (06) 1090-1098
  • 31 Simon K, Sheckley H, Anderson CL, Liu Z, Carney PR. A review of fenfluramine for the treatment of Dravet syndrome patients. Curr Res Pharmacol Drug Discov 2021; 3: 100078